- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02919813
M-gCBT for Women With Provoked Localized Vulvodynia
May 4, 2022 updated by: Catherine M Leclair, MD, Oregon Health and Science University
Mindfulness-Based Group Cognitive Behavior Therapy for Women With Provoked Localized Vulvodynia: A Randomized Pilot Study
The purpose of this study is to learn more about Mindfulness based Group Cognitive Behavior Therapy (M-gCBT) as a treatment for Provoked Localized Vulvodynia (PLV).
M-gCBT is a counseling technique that has been shown to reduce pain and anxiety with other medical conditions, including chronic pain conditions.
The investigators wish to see if participation in M-gCBT course will help reduce anxiety, fear, and pain in women with PLV greater than education alone.
Both techniques use a group setting including other women with PLV.
"Mindfulness-Based Group Cognitive Behavior Therapy for Women with Localized Vulvodynia" is a study designed to learn more about the use of mindfulness based group cognitive behavior therapy for PLV pain and anxiety over education alone.
Participants will be randomized to one of two groups: mindfulness based cognitive behavior therapy or group education seminars.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
M-gCBT is a type of counseling that teaches women to have more control over their pain.
Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
Both groups will be given a binder containing course material at the first session and homework at each session that you will be asked to complete.
The group education seminars will include an informational video clip reviewing an aspect of PLV and sexuality and will be followed by a group discussion facilitated by an instructor.
Each session will involve a teacher and a small group of 6 to 12 women with PLV.
Additionally, women in both groups will be asked to perform a weekly test to measure pain and to complete a daily diary.
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Reported dyspareunia for at least 6 months in non-pregnant, healthy women over aged 18-45 years old meeting Friedrich's criteria for PLV.51
- Qtip Test51-52, 54 mean verbal rating score of ≥4/10 in 4 of 6 defined points of the vestibule (2, 4, 6, 8, 10, 12 o'clock), and have received a Qtip Test score of verbal ≤ 2/10 for the labia majora and minora, intra labial sulcus, and perineum.
- Ability to insert a regular Tampax® tampon
- Baseline tampon test pain score ≥80mm
- Phone access
- Lives within 60 miles with reliable transportation
Exclusion Criteria:
- Pregnancy
- Active counseling or mindfulness training (within 6 months of study)
- Any other clinical reason for dyspareunia (endometriosis pain, chronic pelvic pain, vulvar dermatoses such as psoriasis, lichen sclerosus, etc).
- Impaired cognition or disruptive behavior not conducive to group dynamic
- Planned long term travel or surgery during study period
- Unable or unwilling to complete baseline assessments or agree to be randomized.
- Axis 2 diagnosis, chronic substance abuse, suicidality or disruptive to group dynamic
- Non-English speaking
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: M-gCBT Group
Mindfulness Based Group Cognitive Behavior Therapy (M-gCBT Group) is a type of counseling that teaches women to have more control over their pain.
|
Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
Other Names:
|
|
Active Comparator: Educational Seminars
Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
|
Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Tampon Test
Time Frame: Change from time of enrollment until 6 months after study
|
The change from baseline in pain measured by the Tampon Test at 6 months.
The tampon test is a validated tool used to measure (vulva) vestibular skin pain by having participants insert and remove a tampon.
Participants will be asked to rate their pain along a 100 mm Visual Analog Scale on a scale of 0 (No pain) to 10 (Pain as bad as you can imagine).
This test will occur at baseline and 6 months follow up.
|
Change from time of enrollment until 6 months after study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sexual Distress Survey Response
Time Frame: Change from time of enrollment until 6 months after study
|
Change from baseline in sexual distress at 6 months.
Participants will complete a Female Sexual Distress Scale (FSDS) survey to rate their feelings associated with sexual activities; range 0 (better outcome) - 52 (worse outcome).
The FSDS surveys will be completed at baseline and 6 months follow up.
A negative change in FSDS score from baseline indicates less sexual distress over time (better outcome) and a positive change in FSDS score from baseline indicates more sexual distress over time (worse outcome).
|
Change from time of enrollment until 6 months after study
|
|
Sexual Function Questionnaire Response
Time Frame: Change from time of enrollment until 6 months after study
|
Change from baseline in sexual function at 6 months.
Participants will complete a Female Sexual Function Index (FSFI) survey which asks questions about participants sexual feelings over the past 4 weeks; range 2 (worse outcome) - 95 (better outcome).
The FSFI surveys will be completed at baseline and 6 months follow up.
A negative change in FSFI score from baseline indicates less sexual function over time (worse outcome) and a positive change in FSFI score from baseline indicates more sexual function over time (better outcome).
|
Change from time of enrollment until 6 months after study
|
|
Depression Questionnaire Response
Time Frame: Change from time of enrollment until 6 months after study
|
Change from baseline in depression at 6 months.
Participants will complete the Beck Depression Inventory (BDI-PC) questionnaire, which consists of 21 groups of statements where participants selects which statement best describes how they have been feeling during the past 2 weeks.
Total score = sum of 21 statement subscales; range 0 (better outcome) - 63 (worse outcome).
The BDI-PC surveys will be completed at baseline and 6 months follow up.
A negative change in BDI-PC score from baseline indicates less depression over time (better outcome) and a positive change in BDI-PC score from baseline indicates more depression over time (worse outcome).
|
Change from time of enrollment until 6 months after study
|
|
Anxiety Questionnaire Response
Time Frame: Change from time of enrollment until 6 months after study
|
Change from baseline in anxiety at 6 months.
Participants will complete the General Anxiety Disorder-7 (GAD-7) scale questionnaire.
The GAD-7 consists of 7 problems where participants rate how often they have been bothered by those problems during the past 2 weeks.
Total score = sum of 7 subscales; range 0 (better outcome) - 21 (worse outcome).
The GAD-7 surveys will be completed at baseline and 6 months follow up.
A negative change in GAD-7 score from baseline indicates less anxiety over time (better outcome) and a positive change in GAD-7 score from baseline indicates more anxiety over time (worse outcome).
|
Change from time of enrollment until 6 months after study
|
|
Pain Catastrophizing Scale Response
Time Frame: Change from time of enrollment until 6 months after study
|
Change from baseline in pain catastrophizing at 6 months.
Participants will complete the Pain Catastrophizing Scale survey.
The survey consists of thirteen statements describing different thoughts and feelings that may be associated with pain.
Total score = sum of 13 statement subscales; range 0 (better outcome) - 52 (worse outcome).
The pain catastrophizing surveys will be completed at baseline and 6 months follow up.
A negative change in score from baseline indicates less pain catastrophizing over time (better outcome) and a positive change in score from baseline indicates more pain catastrophizing over time (worse outcome).
|
Change from time of enrollment until 6 months after study
|
|
Quality of Life Questionnaire Response
Time Frame: Change from end of study until 6 months after study
|
Perceived treatment improvement and satisfaction in quality of life questionnaire.
Questionnaires for quality of life at end of group intervention and at 3 months and 6 months follow up.
|
Change from end of study until 6 months after study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 16, 2015
Primary Completion (Actual)
September 30, 2017
Study Completion (Actual)
September 30, 2017
Study Registration Dates
First Submitted
July 19, 2016
First Submitted That Met QC Criteria
September 27, 2016
First Posted (Estimate)
September 29, 2016
Study Record Updates
Last Update Posted (Actual)
May 6, 2022
Last Update Submitted That Met QC Criteria
May 4, 2022
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- OHSU IRB 15221
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.